Alzheimer's Association clinical practice guideline for the Diagnostic Evaluation, Testing, Counseling, and Disclosure of Suspected Alzheimer's Disease and Related Disorders (DETeCD‐ADRD): Executive summary of recommendations for primary care
US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence-based guideline was developed to empower all-including primary care-clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. Through a modified-Delphi approach and guideline-development process (7374 publications were reviewed; 133 met inclusion criteria) an expert workgroup developed recommendations as steps in a patient-centered evaluation process. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high-quality, evidence-supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive-behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health-care systems provide adequate resources, outcomes should improve in most patients in most practice settings. Highlights US clinical practice guidelines for the diagnostic evaluation of cognitive impairment due to Alzheimer's disease (AD) or AD and related dementias (ADRD) are decades old and aimed at specialists. This evidence-based guideline was developed to empower all-including primary care-clinicians to implement a structured approach for evaluating a patient with symptoms that may represent clinical AD/ADRD. This summary focuses on recommendations, appropriate for any practice setting, forming core elements of a high-quality, evidence-supported evaluation process aimed at characterizing, diagnosing, and disclosing the patient's cognitive functional status, cognitive-behavioral syndrome, and likely underlying brain disease so that optimal care plans to maximize patient/care partner dyad quality of life can be developed; a companion article summarizes specialist recommendations. If clinicians use this guideline and health-care systems provide adequate resources, outcomes should improve in most patients in most practice settings.
Authors
- Alireza Atri (ORCID: https://orcid.org/0000-0003-4405-6973)
- Jason Karlawish (ORCID: https://orcid.org/0000-0002-6880-2865)
- María C. Carrillo (ORCID: https://orcid.org/0000-0003-3057-2387)
- Pei‐Jung Lin (ORCID: https://orcid.org/0000-0002-8006-2409)
- Susan Scanland
- Chiadi U. Onyike (ORCID: https://orcid.org/0000-0003-2255-4437)
- David S. Knopman (ORCID: https://orcid.org/0000-0002-6544-066X)
- Mary S. Norman
- Bradford Clark Dickerson (ORCID: https://orcid.org/0000-0002-5958-3445)
- Carolyn Clevenger (ORCID: https://orcid.org/0000-0003-3247-7017)
- Mary Sano
Institutions
- Alzheimer's Association (US)
- Cedars-Sinai Medical Center (US)
- Brigham and Women's Hospital (US)
- Tufts Medical Center (US)
- Mayo Clinic (US)
- Harvard University (US)
- Johns Hopkins University (US)
- Emory University (US)
- Johns Hopkins Medicine (US)
- Massachusetts General Hospital (US)
- James J. Peters VA Medical Center (US)
- Banner Sun Health Research Institute (US)
- Banner Alzheimer’s Institute
- University of Pennsylvania (US)
- Icahn School of Medicine at Mount Sinai (US)
Publication Details
- Journal
- Alzheimer s & Dementia
- Published
- 2024-12-23
- DOI
- https://doi.org/10.1002/alz.14333
- Citations
- 28
- Primary Topic
- Dementia and Cognitive Impairment Research
- Type
- article
- Field-Weighted Citation Impact
- 10.80
Funders
- Alzheimer's Association